

|
Vendevia Group |



|
Kurt R. Gehlsen, Ph.D. Vice President and Chief Scientific Officer, Research Corporation Technologies
As CSO of RTC, Dr. Gehlsen provides scientific leadership in the review and oversight of their biomedical investment activities. He works closely with the company's technology identification, development and business functions. Dr. Gehlsen has 20 years experience working in private and public companies, pharmaceutical product development, basic research, clinical development, regulatory affairs, strategic planning, business development, investor relations and executive management. |
|
Biomedical Venture Development |

|
Chairman
Managing Partner
Managing Partner
CFO and Controller
Advisory Board
Advisory Board
Advisory Board
Advisory Board
Advisory Board
|